Sales figures growing for the first quarter 2020
The Group recorded a significant +15% on the Italian market in the first three months of the current year, thanks especially to the sales performance of the brands SiderAL® and ApportAL®. Foreign sales are uninterrupted too, despite the COVID-19 emergency.
The positive trend continues for PharmaNutra. The company published its 2019 financial statements figures last week highlighting consolidated revenue figures up 15% compared to the previous financial year.
Important numbers, then confirmed by the sales figures for the first quarter 2020 – just as positive and showing a double-digit growth against the previous year – referred to the Group’s two companies active in commercialising nutritional supplements and medical devices PharmaNutra S.p.A. and Junia Pharma S.r.l.
In general, total volume sales on the Italian market in the first three months of the current year were 748,803 pieces compared to 653,434 in the previous year, showing a significant +15%. Results of the excellent performance of a sales force promptly reorganised in smart-working to deal with the emergency caused by the spread of COVID-19.
The company confirmed the positive trend of the brand SiderAL®, created thanks to an innovative, patented Sucrosomial® Technology, an efficient action mechanism that has enabled PharmaNutra to overcome the limits and problems caused by administering oral iron, a mineral with reduced absorption and low gastrointestinal tolerability. As reported by FederSalus, based on January IQVIA data1 related to the food supplement market, SiderAL® was the most sold nutritional supplement in Italy for the fourth month running, with a 10% increase compared to the same period last year.
Total volume sales in Italy in the month of March (290,777 pieces) grew 10% compared to March 2019; with a significant contribution from ApportAL® , the first nutritional supplement combining the properties of 5 Sucrosomial® Minerals (iron, selenium, zinc, iodine, magnesium), vitamins, amino acids and plant extracts. And also, thanks to the sales communication campaign active all over the country in recent weeks, ApportAL® has recorded a significant +22% compared to March 2019.
Foreign market sales are also progressing uninterrupted with very positive figures: the growth in sales volumes in the first quarter 2020 is even higher than the Italian market and goes beyond Group expectations, whereas orders for the second quarter have all been confirmed.
“To keep on growing at a double-digit rate in a complicated moment like the present one shows strength, cohesion and an uncommon feeling of company belonging for which we are especially proud”, declares the President Andrea Lacorte. “Pride, I want to stress, that has nothing to do with the excellent first quarter 2020 figures, but with the fact that it is thanks to these solid values that we were able to take a number of actions to support the National Health System, badly hit by this emergency and to which we are very close”.